Clinical Trials Using Olaratumab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Olaratumab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body.
Location: 15 locations
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies. The present study is open to children with advanced cancer or cancer that has spread to another part of the body. The study has two parts. In each part, a specific dose of olaratumab will be given for 21 days, followed by one of three standard chemotherapy regimens. Participants will only enroll in one part.
Location: 9 locations
A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma
The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).
Location: 5 locations
A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
Location: 2 locations
Doxorubicin Hydrochloride, Dexrazoxane Hydrochloride, and Olaratumab in Treating Patients with Advanced or Metastatic Soft Tissue Sarcoma That Cannot Be Removed by Surgery
This phase II trial studies how well doxorubicin hydrochloride, dexrazoxane hydrochloride, and olaratumab work in treating patients with soft tissue sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment and cannot be removed by surgery. Drugs used in chemotherapy, such as doxorubicin hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies, such as olaratumab, may interfere with the ability of tumor cells to grow and spread. Giving doxorubicin hydrochloride, dexrazoxane hydrochloride, and olaratumab may work better in treating patients with soft tissue sarcoma.
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.
Location: Medical University of South Carolina, Charleston, South Carolina